Home > Analytics > ORCHID PHARMA

ORCHID PHARMA
Intrinsic Value | Fundamental Analysis

BOM : 524372     NSE : ORCHPHARMA    
LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Average [Stock is fairly valued]
Debt : High
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Upward
Pledged Shares : NA
Dec 02,2022
Price(EOD): ₹ 404.60
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
Pharmaceuticals & Drugs
MCap: ₹ 1,650.77 Cr
Value of ₹ 1 Lac invested in ORCHID PHARMA
on Dec 04,2017 (price: ₹ 19.00)

₹ 1 L

₹ 21.29 L

1W : 1.6% 1M : 2.9% 1Y : -0.4%
COMMUNITY POLL
for ORCHID PHARMA
Please provide your vote to see the results
ORCHID PHARMA is part of below Screeners ↓
Best Quarterly Growth Small Cap Stocks
Best 1M Momentum Small Cap Stocks
Industry Peers & Returns1W1M1Y
ORCHID PHARMA 1.6% 2.9% -0.4%
SUN PHARMACEUTICAL INDUSTRIES 0.6% -1.1% 38.8%
DIVIS LABORATORIES 0.2% -10.6% -30.7%
DR REDDYS LABORATORIES 2.5% -1% -5.8%
CIPLA 1% -4% 15.8%
GLAND PHARMA -1.3% -8.4% -51.1%
PIRAMAL ENTERPRISES 4.8% 2.6% -64.3%
CADILA HEALTHCARE 4.1% -4.8% -11.6%
TORRENT PHARMACEUTICALS -0.9% -4.3% 7.9%

FUNDAMENTAL ANALYSIS OF ORCHID PHARMA

 
Fundamentals Score
[ Q(TTM): Sep2022, Y: Mar2022
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]


VALUATION OF ORCHID PHARMA

 
Valuation Score
[As on : Dec 02,2022 ]

Ratio Consolidated
P/E
P/B
P/S
-50.58
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs -32.65 Cr
[Latest Qtr - Sep2022 - Consolidated Results ]

2.55
P/B Calculated based on Book Value of Rs 647.38 Cr
[Latest Year - Mar2022 - Consolidated Results ]

2.6
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 635.75 Cr
[Latest Qtr - Sep2022 - Consolidated Results ]

Financial Ratios →

Insights 💡 There are potential 16% undervalued companies ! Discover More →

FAIR VALUE OF ORCHID PHARMA

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
-71%
-19%
1164%

Insights 💡 You can learn about various Valuation techniques to calculate Intrinsic Value
with our bestselling video course Value Investing - The Ultimate Guide
Take Me There →

SHARE PRICE MOMENTUM OF ORCHID PHARMA


Insights 💡 ORCHPHARMA is one of the top 33% companies with bullish price momentum currently! Discover More →

ORCHID PHARMA vs SENSEX


Insights 💡 You can learn about Basics of Stock Marketing Investing
with our bestselling video course Stock Marketing Investing Simplified
Take Me There →

DEBT OF ORCHID PHARMA

Year Debt/Equity ratio
Standalone Consolidated
2022
2021
2020
Avg_3yrs
0.4
0.66
0.71
0.59
0.41
0.69
0.74
0.61
[Last Annual Data : Mar2022]
Financial Ratios →

PLEDGED PROMOTER SHARES OF ORCHID PHARMA

Pledged Promoter Shares
NA

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad
Shareholding Pattern →

QTRLY RESULTS OF ORCHID PHARMA

Consolidated Q-o-Q Y-o-Y
Revenue
Op Profit
Profit Before Tax
Profit After Tax
26.16%
43.16%
76.42%
76.42%
29.37%
57.69%
80.33%
80.33%
QtrlyTrend
8
Latest Qtr: Sep2022
Quarterly Result Analysis →


ORCHID PHARMA related INDICES

No BSE index found!
No NSE index found

You may also like the below Video Courses


FAQ about ORCHID PHARMA


Is ORCHID PHARMA good for long term investment?

As on Dec 02,2022, the Fundamentals of ORCHID PHARMA look Poor and hence it may not be good for long term investment ! See Financial Performance of ORCHID PHARMA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is ORCHID PHARMA UnderValued or OverValued?

As on Dec 02,2022, ORCHID PHARMA is Fairly Valued based on the estimates of intrinsic value and investors may wait for the buying opportunity once it becomes under valued!

What is the Intrinsic Value of ORCHID PHARMA ?

As on Dec 02,2022, the Intrinsic Value of ORCHID PHARMA is Rs. 499.84 estimated based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 1,413.09
Fair Value [Median EV / Sales Model] : Rs. 499.84
Fair Value [Median Price / Sales Model] : Rs. 32.02
Estimated Median Fair Value of ORCHID PHARMA : Rs. 499.84

The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.

Is ORCHID PHARMA trading at a Premium or Discount?

As on Dec 02,2022, ORCHID PHARMA is trading at a Discount of -19% based on the estimates of Median Intrinsic Value!

SEBI Research Analyst
The Founder of this website, Mr. Rohit Katiyar is registered with SEBI as a Research Analyst [INH000007377].